A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 06 Feb 2018
At a glance
- Drugs TT 701 (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 25 Apr 2016 First patient has been dosed, as reported in a Transition Therapeutics media release.
- 25 Apr 2016 Status changed from not yet recruiting to recruiting, according to a Transition Therapeutics media release.
- 29 Oct 2015 According to a Transition Therapeutics media release, this trial is expected to start in the fourth quarter of 2015.